BIND Therapeutics collaborates with Affilogic

USA-based BIND Therapeutics (Nasdaq: BIND), a company developing targeted and programmable therapeutics called ACCURINS, has signed a research collaboration with fellow biotech, privately-held Affilogic, which developing affinity proteins called Nanofitins that selectively bind and interact with identified targets.

Shares of BIND, which earlier this month announced that it has elected to file a voluntary petition under Chapter 11 of the Bankruptcy Code in the US Bankruptcy Court for the District of Delaware, closed up 13.6% at $057 by end of regular trading on Friday, having risen as much as 35% during the day. The bankruptcy move was precipitated by an April 26 notice from lender Hercules Capital, a venture debt firm that demanded payment in full of the $13.2 million balance on its loan, along with $1.2 million in fees. Complying with that notice would have effectively meant liquidating the company.

Terms of the accord